The global mRNA vaccine patent landscape

Abstract

In light of their quick development and low risk, mRNA vaccines are gradually replacing traditional vaccines. In order to characterize the patent landscape of mRNA vaccines, this study collated mRNA vaccine–related applications that have been registered since 1962. Accordingly, the 1852 patent families were discussed in relation to their temporal distribution, geographic scope, organizational assignees, and co–patenting activities. mRNA vaccines were shown to demonstrate promise in infectious disease, cancer immunotherapy, and allergic disease, with a focus on lipid nanoparticles. Notably, these vaccines are being developed against a backdrop of fierce industrial competition and intensive collaboration with a rise in applications. The findings of this study highlighted cutting–edge inventions, key players, and collaboration dynamics among institutions. By understanding the landscape of mRNA vaccine patents, researchers and those in industry may better comprehend the latest trends in this area, which may also assist relevant decision–making by academics, government officials, and industrial leaders.

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications

“…The number of patent publications relating to mRNA vaccines began to increase in about 1995 and has grown exponentially starting from about 2009 [ 25 ]. According to searches on the Derwent Innovation platform ( https://clarivate.com/products/derwent-innovation/ ), the statistics show more than 9600 related patents were registered by the end of 2021 [ 125 ]. Moreover, there are already over 15,000 patents valid and applied in major countries (such US, JP, EP, etc.)…”

“…According to searches on the Derwent Innovation platform (https:// clari vate. com/ produ cts/ derwe nt-innov ation/), the statistics show more than 9600 related patents were registered by the end of 2021 [125]. Moreover, there are already over 15,000 patents valid and applied in major countries (such US, JP, EP, etc.)…”

Liposomal delivery system/adjuvant for tuberculosis vaccine

“…The COVID‐19 pandemic's progress and its unforeseen worldwide effects have brought attention to the urgent need for safe, dependable and effective vaccines 26,27 . The messenger RNA vaccine family is one of the cutting‐edge immunization classes that has produced exceptional success against infectious disorders during the past 10 years 28,29 . This type of vaccine offers a number of significant advantages over conventional platforms, including the ability for highly quick and flexible vaccine design and production 30,31 .…”

“…26,27 The messenger RNA vaccine family is one of the cutting-edge immunization classes that has produced exceptional success against infectious disorders during the past 10 years. 28,29 This type of vaccine offers a number of significant advantages over conventional platforms, including the ability for highly quick and flexible vaccine design and production. 30,31 Additionally, it has also been demonstrated that attenuated live vaccines are a highly effective method for preventing viral infections 32,33 Subunit vaccines have been introduced as a safer alternative to attenuated live vaccines.…”

American “Digital Curtain” to Isolate China

“…This is consistent with analysis showing that the US holds the most Covid-19 vaccine patents and sits at the centre of this global collaboration network. 9 Medical countermeasures provide protection (and post-exposure management) for military and civilian people against chemical, biological, radiological and nuclear material by providing rapid field-based diagnostics and therapeutics (such as antiviral medications) in addition to vaccines. 10 The race to be the next most important technological powerhouse is a close one between the UK and India, both of which claim a place in the top five countries in 29 of the 44 technologies.…”